Conditions: Obesity Vitamin D Deficiency Psychosis Schizophrenia Schizoaffective Disorder
Keywords: Psychiatric illnesses Vitamin D deficiency Obesity
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications. This weight gain may result in the development of features of the metabolic syndrome or frank diabetes mellitus. There is no consensus on the best way to prevent these complications. The investigators' hypothesis is that daily vitamin D supplementation in these patients will result in decreased levels of the markers of metabolic syndrome with associated reduction in waist circumference.

Detailed description:
In this 8-week open label trial, we will enroll 10 subjects who fulfill the Inclusion Criteria.

Arms:
arm 1: None

Interventions: intervention 1: Ergocalciferols
Intervention descriptions: intervention 1: 2000 international units by mouth daily for 8 weeks.

Protocol document: